NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Nathan Connell: What Is The “Mild Equivalent” For Hemophilia A That Is Achieved While on Emicizumab?
Nathan Connell/LinkedIn
Aug 3, 2025, 17:48

Nathan Connell: What Is The “Mild Equivalent” For Hemophilia A That Is Achieved While on Emicizumab?

Nathan Connell, MD, MPH, FACP, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared an insightful post on LinkedIn:

”A common question that comes up in hemophilia clinic is: What is the “mild equivalent” for hemophilia A that is achieved while on emicizumab? We know that secondary hemostasis isn’t completely normalized for people taking emicizumab, but patients often ask what their (equivalent) factor VIII level would be if it could be measured. At its most basic, disorders of secondary hemostasis are rooted in an inability to generate thrombin, so thrombin generation assays (TGAs) are theoretically an attractive method to offer a window into the answer for this question; however, differences in TGAs and lack of standardization make it difficult to settle on a single number.

This Haemophilia Journal publication by Daniel Kraemmer and colleagues (including Cihan Ay) highlights the heterogeneity in estimates depending on which TGA parameters are utilized in the analysis, and suggests a conservative estimate is anywhere from 15% – 37%, supporting clinical experience with the therapy but highlighting the need for better methods to assess hemostasis in vivo.”

Read the full article here.

Article: Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Authors: Daniel Kraemmer , Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge

Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?

Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.

bleeding disorders Cihan Ay Daniel Kraemmer Emicizumab FVIII Georg Heinze Haemophilia journal Health Hematology Hemophilia Hemostasis Today Ingrid Pabinger Judit Rejtő Medicine Nathan Connell Oliver Königsbrügge Peter Quehenberger TGA thrombin generation assays
NewsFeed